Real-life Results of Grazoprevir/Elbasvir in HCV-Infected PWID: The Zepalive Studi | Juan Macías

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Underdiagnosis and suboptimal care of diabetes mellitus in a French HIV-infected cohort in 2016 - Dr. A. Sautereau

European Workshop on Healthy Living with HIV 2017

HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. Seixas

International Workshop on HIV & Hepatitis Co-infection 2017

Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro

International Workshop on HIV & Hepatitis Co-infection 2017

Implementing PrEP for HIV prevention- Martin Markowitz, MD

Asian Conference on Hepatitis and AIDS (ACHA) 2017

A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti

European HIV Clinical Forum 2016

Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting

European HIV Clinical Forum 2016

Focus on psychosocial needs | Molly Perkins, PhD

International Workshop on HIV & Aging 2016

Transmitted Drug Resistance and First-line ART Treatment Outcomes in Ugandan Children | H. Mugerwa

INTEREST 2016

The Non-adherent Patient A Good or Bad Candidate for CAB+RPV - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022